2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. VEGFR
  5. VEGFR Antagonist

VEGFR Antagonist

VEGFR Isoform Comparison

VEGFR Antagonists (4):

Cat. No. Product Name Effect Purity
  • HY-P9920A
    Ramucirumab (anti-VEGFR)
    		Antagonist 99.36%
    Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.
  • HY-P10833
    VGB3
    		Antagonist
    VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1/Flt-1)/VEGFR2/KDR/Flk-1 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1/Flt-1 and VEGFR2/KDR/Flk-1, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model.
  • HY-P10550
    VGB4
    		Antagonist
    VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research.
  • HY-P10831
    GNQWFI
    		Antagonist
    GNQWFI, an anti-Flt1 peptide, is a VEGFR1/Flt-1-specific antagonist. GNQWFI blocks the interaction of VEGFR1/Flt-1 with various VEGFR1/Flt-1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases.